Bridgeway Capital Management, LLC Avrobio, Inc. Transaction History

Bridgeway Capital Management, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$1.15 - $1.48 $31,509 - $40,552	27,400 Added 11.42%	267,387 $342,000
Q4 2023 Feb 14, 2024	BUY	$1.22 - $1.62 $112,956 - $149,990	92,587 Added 62.81%	239,987 $326,000
Q3 2023 Nov 14, 2023	BUY	$0.98 - $1.62 $40,572 - $67,068	41,400 Added 39.06%	147,400 $226,000
Q1 2023 May 15, 2023	SELL	$0.76 - $1.82 $38,000 - $91,000	-50,000 Reduced 32.05%	106,000 $106,000
Q3 2022 Nov 14, 2022	BUY	$0.68 - $1.11 $14,280 - $23,310	21,000 Added 15.56%	156,000 $100,000
Q2 2022 Aug 15, 2022	SELL	$0.75 - $1.33 $73,575 - $130,473	-98,100 Reduced 42.08%	135,000 $124,000
Q1 2022 May 16, 2022	BUY	$1.29 - $4.04 $103,200 - $323,200	80,000 Added 52.25%	233,100 $308,000
Q4 2021 Feb 14, 2022	BUY	$3.45 - $6.05 $528,195 - $926,255	153,100 New	153,100 $589,000

559K

Ticker AVRO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,773,900
Description
AVROBIO, Inc., a clinical-stage gene therapy company, develops ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose worldwide. Its gene therapies employ hematopoietic stem cells that are collected from patients and modified with a lentiviral vector to insert functional copies of the gene that is defective in the...

Get notified when there are updates to the investment portfolio of Bridgeway Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Bridgeway Capital Management, LLC with notifications on news.